Provided by Tiger Trade Technology Pte. Ltd.

Rocket Pharmaceuticals, Inc.

2.63
+0.09503.75%
Post-market: 2.660.0300+1.14%19:30 EDT
Volume:3.46M
Turnover:9.06M
Market Cap:288.71M
PE:-15.47
High:2.78
Open:2.78
Low:2.52
Close:2.54
52wk High:5.45
52wk Low:2.42
Shares:109.77M
Float Shares:85.39M
Volume Ratio:1.70
T/O Rate:4.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1700
EPS(LYR):-2.0100
ROE:-4.77%
ROA:-28.42%
PB:0.78
PE(LYR):-1.31

Loading ...

Rocket Pharma Swings to Q2 FY26 Net Income of $123.2 Million; R&D Expenses Fall 30.92% to $29.5 Million

Reuters
·
Aug 11

Rocket Pharmaceuticals Q2 EPS USD 1.08

Reuters
·
Aug 11

Rocket Pharmaceuticals, Inc.: Cash, Cash Equivalents and Investments of About $283.7 Mln; Expected Cash Runway into Q2 of 2028

THOMSON REUTERS
·
Aug 11

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

THOMSON REUTERS
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Aug 04

Rocket Pharmaceuticals Inc Expected to Post Earnings of 37 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Rocket Pharmaceuticals - Rp-A501 Well-Tolerated in Initial Three Patients with no Tma or Capillary Leak Syndrome

THOMSON REUTERS
·
Aug 03

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with Rp-A501 Under Modified Phase 2 Protocol for Danon Disease

THOMSON REUTERS
·
Aug 03

Rocket Pharmaceuticals - Engaging with FDA on Pivotal Trial; Regulatory Update Expected in H2 2026

THOMSON REUTERS
·
Aug 03

Quince Therapeutics Names Brigette Roberts CEO in Management Reshuffle

Reuters
·
Aug 01

Rocket Pharmaceuticals Principal Accounting Officer Joseph Manhede Files Initial Beneficial Ownership Statement

Reuters
·
Jul 09

Rocket Pharma Names Joseph Manhede Principal Accounting Officer, Effective July 8

Reuters
·
Jul 01

Rocket Pharmaceuticals sells rare pediatric disease priority review voucher for $180 million

Reuters
·
Jun 12

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

THOMSON REUTERS
·
Jun 12

Bank of America Securities Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Jun 11

Rocket Pharmaceuticals price target raised to $10 from $9 at BofA

TIPRANKS
·
Jun 03

Bank of America Securities Sticks to Its Buy Rating for Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Jun 03

Rocket Pharma to present at Jefferies Global Healthcare Conference

Reuters
·
May 28

Rocket Pharma CEO Gaurav Shah sells 55,684 shares for $171,787.82

Reuters
·
May 27

Rocket Pharmaceuticals shareholders approve stock option exchange program at annual meeting

Reuters
·
May 21